• Responsible for 2B3D’s strategic in-house legal support and oversight of all aspects of 2B3D’s legal affairs, including corporate finance, securities laws regulation and compliance, intellectual property, corporate governance and general corporate matters, both in and out of the metaverse.• Proactively identify and provide risk-weighted advice that balances commercial upside against corresponding legal, financial, operational, and reputational risk of company initiatives incorporating virtual reality platforms for mental health consultation and therapy. • Regularly evaluate the client-facing aspects of the company’s product offerings in light of legal and regulatory requirements.• Secure smart contracts to store NFT information, which bring transparency and efficiency into blockchain transactions.

• Interim Chief Executive and Counsel to a startup biotechnology company focused on producing enzymes from an exclusive array of microbes through a proprietary bioreactor extraction process.• Oversee, identify and execute all of the company’s legal and business development activities, which include foreign and domestic manufacturing agreements, employment and consulting agreements, securities, capital raising, employee stock incentive plan, privacy, licensing, copyright, trademark and trade secret protection. • Work directly with Chief Medical Officer, Chief Technology Offer and marketing team to commercialize lines of skin care (launched February 2016), nutritional supplements (launched March 2016), veterinary care (launched May 2016) and organic agriculture products (ongoing testing).

• Member of management team formed to facilitate the company’s exit from Chapter 11 bankruptcy reorganization (completed September 2011) and financial turn-around (achieving first cash-flow positive quarters in the company’s history).• Head of business development activities, leading all due diligence, deal structure and documentation required to complete both asset acquisitions and divestments.• Drafted and filed Registration Statement on Form S-1, including all amendments thereto, for the company’s underwritten offering of securities, coordinated all due diligence efforts with underwriters’ counsel and filed listing application and received approval for trading on the Nasdaq Capital Market.